Calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor KN-93 is widely used in multiple fields of cardiac research especially for studying the mechanisms of cardiomyopathy and cardiac arrhythmias. Whereas KN-93 is a potent inhibitor of CaMKII, several off-target effects have also been found in expression cell systems and smooth muscle cells, but there is no information on the KN93 side effects in mammalian ventricular myocytes. In this study we explore the effect of KN-93 on the rapid component of delayed rectifier potassium current (I Kr ) in the ventricular myocytes from rabbit and guinea pig hearts. Our data indicate that KN-93 exerts direct inhibitory effect on I Kr that is not mediated via CaMKII. This off-target effect of KN93 should be taken into account when interpreting the data from using KN93 to investigate the role of CaMKII in cardiac function.
Introduction
Calcium/calmodulin-dependent protein kinase II (CaMKII) is in the focus of research because it is known to modulate various cell functions. Pathologic activation of this enzyme is implicated in different forms of cardiac arrhythmias and CaMKII inhibition is reported to prevent or alleviate development of irregular heartbeats [1] [2] [3] [4] [5] . [N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine) is widely used as a pharmacological tool to inhibit CaMKII in several studies [1, 2, 6] . However, besides its primary effect, KN-93 has been found to have off-target effects including an open-channel blockade of some voltage-gated potassium channels [7, 8] . Until now the side effects of KN-93 have been explored on several voltage-dependent potassium channels in smooth muscle cells, atrial myocytes and expression cell systems, but no data are available for ventricular myocytes. Furthermore, those studies were performed at room temperature and the KN-93 concentrations used were equal or higher than that needed for complete inhibition of CaMKII [7] [8] [9] .
In the present work we explore the inhibitory effect of KN-93 on the rapid component of delayed rectifier potassium current (I Kr ) in freshly isolated rabbit and guinea pig ventricular myocytes at body temperature. We used both the traditional voltage clamp and action potential voltage clamp (APC) methods [6, 10] to study the effect of KN-93 on altering the amplitude and the time course of I Kr during AP and to determine the dose-response of I Kr to KN93 treatment.
Methods
All animal handling and laboratory procedures conform to the approved protocols of the local Institutional Animal Care and Use Committee confirming to the Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health (8th edition, 2011). Chemicals and reagents were purchased from Sigma-Aldrich if not specified otherwise. E-4031 and HMR-1556 were from Tocris. All experiments were conducted at 36 ± 0.1°C. and BTY was supplemented with 1 μM HMR-1556 plus 10 μM nifedipine. I Kr was measured as the tail current amplitude (which was calculated as the difference between the peak current and the pedestal current after repolarization).
Statistical analysis
Data are reported as Mean ± SEM. Statistical significance of differences was evaluated using Student's t-test followed by ANOVA. Difference is deemed significant if p b 0.05. ANOVA is used for group-wise comparison. Student's t-test is used for pair-wise comparison. The difference in the mean values is deemed significant if p b 0.05.
Results

KN-93 abolishes I Kr recorded with action potential clamp method
First, we recorded I Kr as the E-4031 sensitive current under APclamp condition when intracellular Ca 2+ cycling was preserved (no exogenous Ca 2+ buffer was used in the pipette solution).
In the first group of experiments E-4031 sensitive current was recorded with the same, pre-recorded (canonical) AP without calcium chelator in the pipette solution (Ca 2+ cycling). As seen in Fig. 1A , I Kr builds up in accelerating manner during AP plateau and reaches a maximum (0.839 ± 0.066 A/F, n = 18) during phase 3. Then the current declines rapidly and reduces to zero when resting membrane potential is reached. 1 μM KN-93 pre-treatment abolished E-4031 sensitive current (Fig. 1B) . No attempt was made to determine current maximum under these circumstances, because of the lack of a distinguishable peak during the AP. We determined and compared the net charge carried by I Kr (Q Kr ) by integrating the current between the AP peak and APD 95 (AP duration measured at 95% repolarization (Fig. 1D) . To visualize the KN93 effect on the ionic currents during AP, we also recorded KN-93 sensitive current under AP-clamp. The KN-93 sensitive current is a composite current displaying multiple negative peaks along the plateau and terminated after a positive hump during phase three of AP (Fig. 1E) (Fig. 1F) .
KN-93 inhibits I Kr measured as tail current under conventional voltageclamp
To verify the above findings observed under AP-clamp, we also recorded I Kr using traditional rectangular voltage-clamp experiments, when I Kr was recorded cytosolic calcium was chelated and I Ks and I Ca,L were blocked with 1 μM HMR-1556 and 10 μM nifedipine, respectively. I Kr was activated by a 3 s long depolarizing pulses to +40 mV from the holding potential of −40 mV on 20 s cycle length. The inhibitory effect of KN-93 on I Kr was measured by the concentration-dependent reduction of tail current amplitude determined following repolarization to holding potential. As shown in Fig. 2C , KN-93 reduced the tail current amplitude in concentration-dependent manner. The inhibitory effect of KN93 developed within 1 min at each drug concentration tested. KN-93 at 1000 nM completely abolished I Kr , as evidence by no E-4031 sensitive current was left after KN93 treatment. The IC 50 value of KN93 is 102.57 ± 9.28 nM and the Hill coefficient is 0.97 ± 0.12.
The blocking effect of KN-93 was found to be voltage dependent under conventional voltage clamp conditions with buffered cytosolic calcium (Fig. 2D) . When KN-93 was used in 100 nM concentration (~IC 50 ) the inhibitory effect increased by 65.5 ± 12.4% between − 30 and + 50 mV (p slope b 0.01). To test whether the inhibitory effect of KN93 on I Kr is unique to rabbit or exists also in other mammalian species, we examined the effect of 1 μM KN-93 on I Kr recorded from guinea pig ventricular myocytes. The same pipette and bath solutions were used as previously described in rabbit experiments under conventional voltage clamp conditions, except that the voltage command was adapted to the different kinetics of guinea pig I Kr (see Fig. 2 
panel E).
Like in rabbit cells, 1 μM KN-93 completely abolished the tail current indicating that I Kr in guinea pig is also sensitive to KN-93.
Discussion
Our findings indicate that KN-93 exerts direct inhibitory effect on I Kr in mammalian ventricular myocytes and several lines of evidence converge to suggest that this KN93 effect is not mediated through CaMKII. First, the inhibitory effect of KN93 on I Kr develops within 1 min, a time period too short to be explained by the inhibition of CaMKII [11] . Second, the IC 50 value for KN93 inhibition of I Kr determined in our experiments (102.57 ± 9.28 nM) is significantly lower than the previously reported IC 50 value of KN-93 (N 300 nM) for inhibiting CaMKII [12, 13] . Third, the inhibitory effect of KN-93 was also present when cytosolic calcium was chelated by 10 mM BAPTA, which should alter the CaMKII activity. Fourth, the inhibitory effect of KN-93 displayed voltage sensitivity. Fifth, KN-92 also inhibited I Kr , even though it does not inhibit CaMKII.
Our present observations are in strong agreement with Rezazadeh et al. who demonstrated in transfected HEK293 cells that intracellular dialysis with 1 μM KN-93 for 5 min has no effect on the hERG current. Nevertheless, extracellular application of the same concentration of KN-93 resulted in a rapid inhibition of the current [7] . When KN-93 is used in 1 μM concentration to block CaMKII, I Kr is completely blocked therefore E-4031 cannot prolong AP.
The inhibitory effects of KN-93 on I Kr in mammalian ventricular myocytes were first analyzed in this study. Our most important finding is that KN-93 exerts a direct inhibitory effect on I Kr in concentrations substantially lower than that required to inhibit CaMKII. This inhibitory potential must be taken into consideration when KN-93 (or KN-92) is used in cardiac research, especially in arrhythmia studies when I Kr contributes significantly to shaping the cardiac action potential. 
